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Introduction. The “two-week wait” was established as a potential means of diagnosing malignant tumours earlier. This paper
investigated whether these clinics are leading to earlier diagnosis of malignant soft-tissue lumps. Method. We identiﬁed all referrals
to our centre from a database over a 4-year period. Results. 2225 patients were referred to our unit for investigation of a soft-
tissue mass. 576 (26%) were referred under the “two-week wait” criteria. 153 (27%) of which were found to have a malignant or
borderline malignant diagnosis. 1649 patients were referred nonurgently. 855 (52%) of which were diagnosed with a malignant
or borderline lesion. The average size at diagnosis was 9.4cm with no diﬀerence in size between the diﬀerent referral routes.
Conclusion. There is little evidence that the two-week wait clinic is leading to earlier diagnosis of soft-tissue sarcomas with the
majority still being referred nonurgently.
1.Introduction
The Department of Health set up the “two-week wait”
directive after concerns of diagnostic delay in patients with
suspicion of cancer [1]. The directive requires that patients
should be seen at a referral centre within two-weeks and that
a diagnosis should be obtained within 31 days of referral.
For those with proven malignancy treatment should then
commence within a further 31 days.
There has been considerable controversy about the ben-
eﬁts of two-week wait clinics with some claiming that they
will not improve the diagnosis of patients with malignancy
and others that they will delay diagnosis and management
of other nonmalignant conditions. The diagnostic yield of
malignancy has also varied widely from 9.4% to 16.4%
for bowel and breast cancer, respectively, [2, 3]. One study
looking into urological malignancies [4] found that 11
out of 35 patients (31.4%) referred with a high PSA had
prostate cancer, but most cases were beyond cure. It also
found that only one of 19 patients (5.3%) referred with a
testicular lump had cancer. They concluded that the scheme
as a whole was unlikely to improve cancer outcomes for
urological cancers. There remains uncertainty of the value
of two-week wait clinics in expediting the diagnosis of
cancer.
Only one paper has thus far reported on the eﬃciency
of these clinics for sarcoma patients, demonstrating that 10
out of 40 patients referred had a malignant tumour (25%).
However, less than 7% of all referrals to that unit came
through this system and most of the patients diagnosed had
bone tumours [5].
Soft-tissue sarcomas are a rare type of cancer with
about 2000 cases a year in the UK [6]. Delays in diagnosis
are frequent and the average size at diagnosis remains at
about 10cm [7, 8]. Guidance was ﬁrst published in 1999
highlighting worrying features that should prompt referral
and this was reiterated in the next version of the guidance in
2005 [9, 10]. These criteria are now widely used to instigate a
two-week referral for a suspected Soft-tissue sarcoma.
The aim of this paper was to investigate how eﬀective
the “two-week wait” system was in diagnosing malignancy in
Soft-tissue lumps and what proportion of patients eventually
found to have malignancy were referred through this route
for Soft-tissue lesions. We also investigated whether as a
result of a two-week referral patients were diagnosed earlier
and thus whether their tumours were smaller.2 Sarcoma
2. Methods
Since2005, theoncologydatabaseatourcentrehasbeenable
to identify the type of referral for all patients referred to the
unit. This includes the type of referral (i.e., routine or urgent
under the two-week wait) and where the referral has come
from (i.e., GP or hospital doctor). We analysed data from 1st
November 2005 to 30th April 2009 on all patients referred to
our Unit with a possible Soft-tissue sarcoma.
Weidentiﬁeddetailsaboutthepatients’diagnosisandthe
size of the tumour at diagnosis, their referral route, that is,
who referred the patient and whether they were referred on
purely clinical suspicion or whether they had had a biopsy
or imaging prior to referral. Patients referred from the local
region were identiﬁed by postcode and compared with those
referred from outside the region. The ﬁnal diagnosis was
used to identify whether the patient did indeed have a Soft-
tissue sarcoma or some other diagnosis.
3. Results
During the time period of this study, 364 patients were
referred directly to our unit on clinical suspicion alone of a
possible Soft-tissue sarcoma, without any prior investigation
as per the guidelines. 48 of these patients (13%) had a
malignant or borderline lesion with the remainder having a
benign process or no abnormality.
Another 212 patients had undergone investigations prior
to referral, either organized by their local hospital or by
their GP which had raised the possibility of a sarcoma being
present. Of these, 104 (49%) had a malignant or borderline
lesion. 75 of the 104 had undergone imaging at their local
hospital following a two-week wait referral there which had
raised the suspicion of malignancy. 16 patients had been
referred following imaging organized by their GP which had
raised the suspicion of malignancy. 13 patients had been
referred under the two-week wait following the unexpected
diagnosis of sarcoma following excision of a lump, three by
their GP and ten at their local hospital.
During the same time period 1649 patients were referred
non urgently to our unit for investigation of a Soft-tissue
lesion. In this group there were 855 malignant or borderline
lesions of which 520 were Soft-tissue sarcomas, 83 were Soft-
tissue cancers, 40 were bone sarcomas, 56 were non sarcoma
bone cancers and 156 borderline lesions.
In total during the time period of this investigation,
610 Soft-tissue sarcomas were diagnosed of which only 90
(14.8%) were referred via the “two-week wait” and the other
520 (85.2%) via routine referral. 62 (10.2%) of the 610 Soft-
tissue sarcomas were via GP referrals direct to the unit and
548 (88%) were tertiary referrals from other consultants.
The average size of all the Soft-tissue sarcomas was
9.4cm. The mean size of those diagnosed following urgent
referral under the two-week wait was 10.1cm compared to
9.3cm for those referred routinely (P = .28). However the
averagesizeofthosereferreddirectlytotheunitbyGPsunder
the two-week wait was 11cm compared to 9.3cm for those
referred urgently under the two-week wait to other hospitals
ﬁrst (P = .18).
Overall 27.5% of the sarcomas were superﬁcial to the
fascia and the proportion that were superﬁcial was virtually
the same no matter what the referral route. 29% of the
sarcomasreferredbytheurgenttwo-weekwaitwerefoundto
have a superﬁcial STS compared with 27% detected through
the non urgent route.
There was also no detectable diﬀerence in the location of
the tumours diagnosed by the two diﬀerent routes. Overall
the most common site was the thigh where 35% of all
the Soft-tissue sarcomas were located. Although 43% of the
Soft-tissue sarcomas diagnosed by the two-week wait were
in the thigh, 33% of those referred through other routes
were also in the thigh (P = .21). There was no discernible
diﬀerence in the size or site of the tumours when comparing
where patients were referred from but most of the patients
with subcutaneous sarcomas were referred from the West
Midlands.
4. Discussion
The aim of this paper has been to investigate the eﬀectiveness
ofthetwo-weekwaitclinicindiagnosingmalignancyinSoft-
tissue lumps. Of patients referred directly to our unit by
local GPs, using clinical criteria alone, 13% had a malignant
or borderline lesion. If the patient had imaging or biopsy
suggestive of malignancy prior to referral, the diagnostic rate
not surprisingly increased to 49%.
One of the major ﬁndings of this study however was that
the “two-week wait” clinics only picked up 90 out of 610
Soft-tissue sarcomas that were diagnosed (14.8%), with the
remainder being referred by other routes. There was only a
minimal diﬀerence in size between the tumours at diagnosis,
no matter how they were referred, which is very disappoint-
ing. The overall size of 9.4cm is still considerably in excess of
other series, for example the Scandinavian Sarcoma Group
quote an average size of around 7cm and a recent paper
from Italy quotes 6cm [11, 12]. It is almost double the size
indicated in the Guidance to prompt referral [9].
The reasons for delays in diagnosis of Soft-tissue sarco-
mashavepreviouslybeenexploredandarepartduetolackof
both patient and doctor awareness, with considerable delays
at every step of the pathway [7].
Our data suggests that the majority of patients eventually
found to have Soft-tissue sarcomas are still being referred
non urgently to local hospitals for investigation. The reason
for this is not clear but may be because of patient choice or
GPs not considering the potential diagnosis of malignancy
in lumps and bumps. This was one of the reasons why
diagnostic clinics were recommended as part of the NICE
guidance “Improving outcomes for patients with sarcomas”
[13]. Each English Cancer Network has now deﬁned where
it’s “diagnostic clinic” should be and this will hopefully allow
a more rapid diagnostic pathway for this group.
There is no doubt however that there remains poor
public awareness of the signiﬁcance of Soft-tissue lumps.
The importance of identifying breast lumps is well known
and women are advised to regularly self-check and there
is a national screening program. The average size of breastSarcoma 3
cancers now diagnosed is 2.1cm compared with almost
10cm for Soft-tissue sarcomas [14]. Earlier diagnosis when
the tumour is smaller will lead to improved outcomes for
patients with sarcomas [15, 16].
Theotherinterestingﬁndingformthisstudywasthehigh
incidence of bony lesions identiﬁed even though the patients
were referred ostensibly with a Soft-tissue lesion. Both
benign and malignant lesions protruding from a bone (e.g.,
an osteochondroma or a chondrosarcoma) may simulate a
Soft-tissue mass leading to the confusion. Clearly, in most
cases an X-ray would clarify the nature of the underlying
lesion and this may be considered to be a useful investigation
to be carried out in cases of uncertainty, either by the GP or
the diagnostic clinic
This study has demonstrated that up until now the
two-week wait referral system has made little diﬀerence to
improve the diagnosis of Soft-tissue sarcomas. Patients are
still being diagnosed late, when the tumours have reached
a considerable size. Whether this is because of lack of
patientorGPconcernrequiresfurtherinvestigation.Thefact
that so few patients with proven Soft-tissue sarcomas were
referred through the very system designed to speed up the
diagnostic pathway is also disappointing and suggests the
need for increased GP awareness of the optimum pathway
for early diagnosis. Further initiatives are needed to heighten
awareness of the potential worrying features of Soft-tissue
lumps and bumps and to identify the most speciﬁc factors
that could lead to earlier diagnosis. As far as Soft-tissue
sarcomas are concerned, the “two-week wait” pathway does
not seem to have been helpful. The suggestion by Pencavel et
al. thatpatients with suspicious lumps should be investigated
by ultrasound prior to referral may have some merit but will
rely very much on the quality of who is doing the scan [17].
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